GLENMARK

Ichnos Glenmark Innovation (IGI), part of Glenmark on Monday said its novel trispecific antibody, ISB 2001, demonstrated deep and durable responses in relapsed or refractory multiple myeloma (RRMM) in the Phase 1 dose-escalation studies. ISB 2001 is designed to bind to three different targets or antigens - BCMA, CD38, and CD3. The company presented the data at the 2025 ASCO Annual Meeting in Chicago. The study, conducted across six U.S. and Australian centers, enrolled 35 heavily pretreated patients who had already failed a median of six prior therapies—including CAR-T, bi-specifics, and anti-CD38 agents. “Responses to ISB 2001 highlight its remarkable anti-myeloma activity, even in quad-exposed patients,” said Professor Hang Quach, Director of Hematology at St. Vincent’s Hospital Melbourne. “With unprecedented potency and tolerability, ISB 2001 has the potential to redefine the treatment landscape for RRMM.”